A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission

Leukemia

Volumn 26, Issue 11, 2012, Pages 2428-2431

  Boumber, Y ^a   Kantarjian, H ^a   Jorgensen, J ^a   Wen, S ^a   FaDerl, S ^a   Castoro, R ^a   Autry, J ^a   Garcia Manero, G ^a   Borthakur, G ^a   Jabbour, E ^a   Estrov, Z ^a   Cortes, J ^a   Issa, J P ^a   Ravandi, F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CLOFARABINE; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; CELLULITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; LETTER; LEUKEMIA REMISSION; LOW DRUG DOSE; MAINTENANCE CHEMOTHERAPY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; REMISSION INDUCTION;

EID: 84869095050     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.153     Document Type: Letter

References (14)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062. (Pubitemid 29451802)
2. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
3. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 2006; 106: 1794-1803.
4. Cashen AF, Schiller GJ, O'Donnell MR, Multicenter DiPersio JF. phase II study of decitabine for the first-line treatment of olDer patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 556-561.
5. Kroeger H, Jelinek J, Estecio MR, He R, Kondo K, Chung W et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 2008; 112: 1366-1373.
6. Agrawal S, Unterberg M, KoschmieDer S, zur Stadt U, Brunnberg U, Verbeek W et al. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res 2007; 67: 1370-1377.
7. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010; 28: 605-613.
8. Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K et al. RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res 2007; 67: 1997-2005. (Pubitemid 46424216)
9. Wong KY, So CC, Loong F, Chung LP, Lam WW, Liang R et al. Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One 2011; 6: E19027.
10. San Miguel JF, Vidriales MB, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001; 98: 1746-1751.
11. Stone RM. Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML? Best Pract Res Clin Haematol 2011; 24: 509-514.
12. Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Lo-Coco F et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012; 119: 332-341.
13. Estecio MR, Gharibyan V, Shen L, Ibrahim AE, Doshi K, He R et al. LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One 2007; 2: E399.
14. Bullinger L, Ehrich M, Dohner K, Schlenk RF, Dohner H, Nelson MR et al. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood 2010; 115: 636-642.